List of Excipients in Branded Drug ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE

« Back to Dashboard

Generic Drugs Containing ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE

Company	Ingredient	NDC	Excipient
AvKARE	aspirin and extended-release dipyridamole	42291-116	BUTYL ALCOHOL
AvKARE	aspirin and extended-release dipyridamole	42291-116	CELLULOSE, MICROCRYSTALLINE
AvKARE	aspirin and extended-release dipyridamole	42291-116	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE?

# Of NDCs	Excipient
4	AMMONIA
5	BUTYL ALCOHOL
2	CAPRYLIC/CAPRIC MONO/DIGLYCERIDES

Aspirin and Extended-Release Dipyridamole: Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: November 9, 2026

Aspirin and extended-release dipyridamole is an oral antiplatelet combination marketed in the United States as Aggrenox. Each hard capsule contains 25 mg aspirin for immediate release and 200 mg extended-release dipyridamole. The product is indicated to reduce the risk of stroke in patients with prior ischemic stroke or transient ischemic attack.[1]

The commercial opportunity is primarily in generic supply, differentiated modified-release formulations, excipient substitution, regional launches, and manufacturing improvements. Core composition-of-matter protection is no longer the principal barrier. Product performance depends on reproducing dipyridamole release, maintaining aspirin stability, controlling capsule content uniformity, and demonstrating bioequivalence.

What is the formulation strategy for aspirin and extended-release dipyridamole?

The product uses a dual-release design:

Component	Dose per capsule	Release objective	Formulation role
Aspirin	25 mg	Immediate release	Rapid antiplatelet activity
Dipyridamole	200 mg	Extended release	Sustained exposure over the dosing interval
Dosage form	1 hard capsule	Oral administration	Separates the two release profiles

The approved product is taken twice daily. The label instructs patients to swallow the capsule whole and not crush or chew it because modification can affect the extended-release performance of dipyridamole.[1]

Dipyridamole has limited aqueous solubility, making particle size, wetting, granulation, polymer selection, and dissolution control important. Aspirin introduces a separate stability problem because it can hydrolyze to salicylic acid in the presence of moisture. The formulation therefore has to protect aspirin while providing reliable immediate release.

The formulation is more complex than a conventional aspirin capsule. A manufacturer must control two active pharmaceutical ingredients with different release targets, chemical stability profiles, and dose ratios.

Which excipients are used in the marketed product?

The Aggrenox label identifies a broad excipient system that supports capsule manufacture, modified release, coating, color, and stability.[1]

Excipient or excipient class	Likely function
Acacia	Binder or suspending aid
Colloidal silicon dioxide	Glidant and flow aid
Corn starch	Filler, disintegrant, or processing aid
Lactose monohydrate	Diluent
Microcrystalline cellulose	Diluent and compaction aid
Povidone	Binder
Sucrose	Pellet or coating substrate
Methacrylic acid copolymer	Functional polymer for pH-dependent or delayed release
Talc	Anti-tacking and processing aid
Triethyl citrate	Plasticizer for polymer coating
Titanium dioxide	Opacifier and pigment
FD&C Red No. 40 and D&C Yellow No. 10	Colorants

The exact functional allocation depends on the specific multiparticulate architecture and manufacturing process. The listed excipients indicate a formulation built around coated dipyridamole particles or pellets rather than a single homogeneous matrix capsule.

The principal excipient value lies in the release-control system. Methacrylic acid copolymer and triethyl citrate can create a pH-sensitive coating. Sucrose, acacia, povidone, starch, and cellulose-based materials can support pellet formation and mechanical integrity. Silicon dioxide and talc address powder flow and coating behavior.

What excipient attributes matter most for generic development?

A generic formulation must match the reference product’s in vitro dissolution profile and meet FDA bioequivalence requirements. The formulation does not need to use identical excipients, but any substitution must preserve product performance and avoid new safety or regulatory concerns.

The highest-value excipient attributes are:

Moisture control

Aspirin is vulnerable to hydrolysis. Hygroscopic fillers, high water activity, residual solvent, and permeable packaging can accelerate degradation. Low-moisture excipients and controlled humidity during blending, encapsulation, and storage are commercially important.

High-risk substitutions include:

• Replacing lactose with a more hygroscopic diluent without compensating packaging controls.
• Increasing aqueous granulation exposure.
• Using polymers with variable residual moisture.
• Changing capsule-shell composition without evaluating water transmission.

Release reproducibility

Dipyridamole release is sensitive to:

• Polymer grade and molecular-weight distribution.
• Coating weight gain.
• Plasticizer concentration.
• Particle-size distribution.
• Pore formation and coating defects.
• Gastric and intestinal pH conditions.
• Agitation during dissolution testing.

Excipient suppliers that provide narrow-specification functional polymers, consistent particle size, and validated coating performance can capture value even when the ingredient itself is a commodity.

Capsule fill uniformity

The product contains a relatively low aspirin dose compared with the dipyridamole load. Segregation risk is therefore material. Particle-size matching, density control, ordered mixing, and engineered carrier systems can improve content uniformity.

Dissolution robustness

The formulation should maintain its release profile across normal manufacturing variation. A process that meets dissolution only at the center of the design space is commercially weak. A robust design can reduce batch failures, investigations, and regulatory questions.

What excipient strategies can create commercial differentiation?

Low-moisture immediate-release aspirin phase

A manufacturer can use direct blending, dry granulation, or low-water processing for the aspirin fraction. The objective is to reduce hydrolysis while preserving rapid disintegration.

Potential excipient options include:

• Low-moisture microcrystalline cellulose.
• Spray-dried lactose with controlled water content.
• Coprocessed cellulose-starch systems.
• Low-substituted hydroxypropyl cellulose as a disintegrant.
• Silicified microcrystalline cellulose for improved flow.

The commercial advantage is not necessarily patent exclusivity. It is lower degradation, improved shelf-life performance, and lower process complexity.

Multiparticulate dipyridamole system

Multiparticulate technology is well suited to extended release because it distributes drug across numerous coated units. It can reduce the impact of localized coating defects and improve dose distribution.

Possible designs include:

• Drug-layered sugar or cellulose spheres.
• Matrix pellets coated with a functional polymer.
• Multiple polymer populations with different release rates.
• Coated mini-tablets filled into a capsule.
• pH-responsive pellets combined with an immediate-release aspirin fraction.

A multiparticulate approach can also support dose flexibility and reduce the risk of dose dumping compared with a single-unit matrix system, although performance must be demonstrated experimentally.

Alternative functional polymers

Methacrylic acid copolymers are established pharmaceutical excipients, but suppliers may offer competing grades based on acrylic or methacrylic chemistry. Ethylcellulose, hypromellose, polyvinyl acetate, and lipid-based systems can also be evaluated.

Substitution requires attention to:

• Polymer permeability.
• Film formation temperature.
• Plasticizer compatibility.
• Coating uniformity.
• Storage stability.
• Dissolution at different pH values.
• Supplier change control.

A polymer change that preserves average dissolution but changes the shape of the release curve may still affect bioequivalence.

Colorant and capsule-shell substitution

Colorants are a secondary opportunity but can matter for regional commercialization. A manufacturer may seek:

• Aluminum-lake alternatives.
• Iron-oxide-based colors.
• Colorant-free capsules.
• Titanium-dioxide-free shells where local requirements favor them.
• Vegetarian capsule shells based on hypromellose or pullulan.

These changes can support market access in jurisdictions with different excipient preferences. They also create comparability and stability work because shell permeability and mechanical behavior can change.

What patents protect aspirin and extended-release dipyridamole?

The principal historic protection covered the combination and the modified-release dipyridamole formulation rather than aspirin itself. Aspirin is a long-established generic active ingredient with no meaningful composition-of-matter barrier.

Historic patent categories included:

Patent category	Protected subject matter	Current commercial relevance
Combination patents	Aspirin plus extended-release dipyridamole	Primarily expired or commercially exhausted
Modified-release patents	Dipyridamole pellets, coatings, and release profiles	Relevant to formulation design and freedom-to-operate analysis
Method-of-use patents	Stroke-risk reduction and antiplatelet use	May affect historical Orange Book strategy, but generally weak against generic substitution after expiry
Manufacturing patents	Pellet formation, coating, blending, and encapsulation	Potentially relevant if unexpired claims remain in a jurisdiction
Packaging or stability patents	Moisture protection and storage systems	Usually narrower and less important than formulation claims

The original Aggrenox product was approved in 1999, and the commercial market has moved beyond the period when the branded product could rely on broad exclusivity.[1,2] FDA Orange Book review remains necessary for a live patent count, listed patent status, and the exact expiration dates applicable to an individual ANDA.[2]

A development program should not assume that an expired formulation patent eliminates all risk. A new generic process can still implicate later patents directed to specific coating compositions, pellet structures, dissolution profiles, or manufacturing conditions.

When did aspirin and extended-release dipyridamole lose exclusivity?

The product’s core market exclusivity has expired. Generic competition has entered the U.S. market, and the product is no longer protected by an active new-drug exclusivity period comparable to a newly approved branded medicine.[2,3]

The relevant exclusivity layers are:

Exclusivity layer	Position
New chemical entity exclusivity	Not applicable to the current product lifecycle
Original combination exclusivity	Expired
Pediatric exclusivity	Any historical period has expired
Formulation patents	Historic rights have largely expired; specific later claims require review
Method-of-use rights	Historical and generally expired or commercially limited
Regulatory exclusivity for current generics	Depends on individual ANDA approval history

Because the product is a small-molecule combination, biosimilar regulation does not apply. Competition proceeds through the ANDA pathway rather than the 351(k) biosimilar pathway.[3]

What is the FDA and Orange Book status of Aggrenox?

Aggrenox was approved under NDA 020535 for secondary prevention of stroke in patients with prior ischemic stroke or transient ischemic attack.[1,2]

The regulatory status has four commercial implications:

1. The product is an FDA-approved prescription drug.
2. It is a fixed-dose combination of two established small molecules.
3. Generic manufacturers can use the ANDA pathway if they demonstrate pharmaceutical equivalence and bioequivalence.
4. Orange Book listings, including any remaining patent or exclusivity information, control the timing and structure of ANDA certifications.

A generic applicant generally evaluates Paragraph I, II, III, or IV certifications depending on the status of listed patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed product.[3]

For this product, the key challenge is usually not proving that aspirin and dipyridamole are known active ingredients. It is demonstrating that the proposed release profile and exposure are equivalent to the reference product.

Which companies are challenging the Aggrenox market?

The market has been opened by generic manufacturers rather than biosimilar developers. Generic competition can come from companies with expertise in:

• Modified-release multiparticulate systems.
• Hard-capsule filling.
• ANDA development.
• Low-dose/high-dose combination products.
• Cardiovascular and antiplatelet portfolios.

The strongest competitive position belongs to manufacturers that can reproduce the reference dissolution profile without relying on the original supplier network or identical excipient grades.

Generic entrants can compete through:

• Lower acquisition cost.
• Multiple-source supply.
• Regional tenders.
• Medicaid and managed-care contracting.
• Authorized or private-label distribution.
• Shorter lead times during branded supply interruptions.

The product is less attractive for a commodity-only manufacturer because modified-release failure, aspirin degradation, or dissolution variability can erase the margin advantage.

What Paragraph IV and litigation risks affect the product?

Paragraph IV risk is lower than it was during the original patent term, but it is not automatically zero. A new applicant must evaluate:

• Unexpired Orange Book-listed patents.
• Later-issued formulation patents.
• Coated-pellet claims.
• Release-profile claims.
• Manufacturing-process patents.
• Patent rights in target export markets.

A Paragraph IV strategy is commercially attractive only when the expected launch value exceeds litigation cost and the probability of invalidity or noninfringement is credible. For an older, genericized product, the economic value of litigation may be limited unless the applicant can secure early market entry or has a large cardiovascular portfolio.

Historic litigation involving the product should be separated from current launch risk. Expired patents may explain why a generic first entered the market, but they do not establish freedom to operate for a newly optimized formulation.

What manufacturing and intellectual-property barriers remain?

The main barriers are technical and operational:

Aspirin degradation

Manufacturers need validated controls for moisture, temperature, and packaging. Blister packaging or high-barrier bottles may be necessary depending on stability data.

Dipyridamole dissolution

A formulation can fail bioequivalence even when assay and content uniformity are acceptable. Dissolution method sensitivity is a major development risk.

Pellet coating

Coating equipment, atomization, drying capacity, and endpoint control can determine commercial yield. Scale-up from laboratory fluid-bed coating to commercial production is a material risk.

Excipient supply

Functional polymers, capsule shells, and colorants may have limited qualified suppliers. A dual-source strategy can reduce interruption risk but requires comparability work.

Combination-product process control

The aspirin fraction and dipyridamole fraction may need separate processing before final encapsulation. This increases in-process testing and batch-record complexity.

How does the product compare with aspirin alone, dipyridamole alone, and clopidogrel?

Product	Release profile	Main commercial advantage	Formulation complexity
Aspirin alone	Immediate release	Low cost and broad availability	Low
Dipyridamole ER alone	Extended release	Single active ingredient	Moderate
Aspirin plus dipyridamole ER	Immediate plus extended release	Fixed-dose combination and adherence convenience	High
Clopidogrel	Immediate release	Simple once-daily generic tablet	Low to moderate

Aspirin plus extended-release dipyridamole has higher formulation complexity than aspirin or clopidogrel. Its commercial rationale depends on clinical positioning, prescriber preference, payer coverage, and patient adherence. Clopidogrel creates substantial competitive pressure because it is inexpensive, simple to manufacture, and widely used in antiplatelet therapy.

The fixed-dose combination can still support niche opportunities where clinicians prefer the aspirin-dipyridamole regimen or where adherence benefits offset the higher product cost.

What commercial opportunities exist for excipient suppliers and manufacturers?

The most credible opportunities are:

1. Low-moisture excipient systems that reduce aspirin degradation.
2. Coated-pellet technologies that improve dipyridamole dissolution robustness.
3. Titanium-dioxide-free or colorant-reduced capsule systems.
4. Vegetarian capsule shells for selected international markets.
5. Co-processed excipients that improve flow and content uniformity.
6. Dual-source functional polymer packages.
7. Contract manufacturing for regional generic launches.
8. Private-label and hospital-tender supply.
9. Stability-enhancing packaging and desiccant systems.
10. Formulation-development services for ANDA applicants.

The highest-value commercial proposition is a complete platform combining excipient supply, formulation know-how, coating process parameters, analytical methods, and regulatory support. Commodity excipient supply alone is less defensible.

What generic launch scenarios exist?

Base-case generic launch

A manufacturer uses a conventional multiparticulate formulation, secures ANDA approval, and competes primarily on price. Margin depends on scale, supply reliability, and payer access.

Premium generic launch

A company differentiates through improved capsule shell composition, lower moisture exposure, or packaging designed for hot and humid markets. The product remains an ANDA generic but may achieve better supply contracts.

Regional formulation launch

A manufacturer develops a formulation tailored to excipient restrictions, capsule preferences, or tender requirements in Europe, Latin America, Asia, or the Middle East. Regional regulatory dossiers may require separate bioequivalence or bridging work.

Technology-licensed launch

An excipient supplier or formulation company licenses a coating process, polymer system, or manufacturing platform to a generic manufacturer. Royalty potential is highest when the technology lowers failed-batch risk or enables a difficult bioequivalence program.

Key Takeaways

• Aspirin and extended-release dipyridamole is a technically demanding generic combination because it requires immediate aspirin release and sustained dipyridamole release in one capsule.
• Aspirin stability and dipyridamole dissolution are the two central formulation risks.
• The principal excipient opportunity is in functional release-control systems, low-moisture processing, and robust pellet coating.
• Aggrenox’s core exclusivity has expired, and generic competition is established.
• Biosimilar risk is irrelevant because the product contains small-molecule actives.
• Paragraph IV exposure is mainly relevant to any later formulation or manufacturing patents, not to the original active ingredients.
• Commercial value is strongest for integrated excipient and manufacturing platforms rather than undifferentiated commodity supply.
• Clopidogrel and aspirin alone create significant price competition, limiting the upside of a generic launch unless the manufacturer has scale or differentiated supply capabilities.

FAQs

Can aspirin and extended-release dipyridamole be reformulated as a tablet?

Yes, but a tablet would need to preserve the immediate-release aspirin fraction and the extended-release dipyridamole fraction. A bilayer tablet, coated multiparticulate tablet, or tablet containing coated pellets could be evaluated. The regulatory burden would include comparative dissolution and bioequivalence testing.

Which excipient is most important for dipyridamole extended release?

The functional polymer system is usually the most important excipient category. Polymer grade, coating weight, plasticizer level, and film permeability determine the release profile. No single excipient can be selected independently of the coating process.

Is lactose suitable for an aspirin-containing formulation?

Lactose can be suitable and is present in the marketed product. Its use requires control of moisture, grade, particle size, and compatibility with the manufacturing process. The critical issue is the finished product’s aspirin stability, not lactose alone.

Does a generic manufacturer need to use the same excipients as Aggrenox?

No. FDA generic regulations generally permit different inactive ingredients if the product remains pharmaceutically equivalent, safe, stable, and bioequivalent. The applicant must justify the formulation and address any excipient-specific safety or performance concerns.[3]

Can excipient substitution create a new patent position?

Yes. A novel coating composition, multiparticulate architecture, stability-enhancing system, or manufacturing process may support new patent claims. Patent strength depends on novelty, nonobviousness, written description, enablement, and the ability to show a meaningful technical effect.

References

1. Boehringer Ingelheim Pharmaceuticals, Inc. (2023). Aggrenox: Aspirin and extended-release dipyridamole capsules, prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process for generic drugs. FDA.